Introduction
Sorafenib, 4-pyridine 2-carboxylic acid methylamide 4-methylbenzenesulfonate, is an orally administered multikinase inhibitor that exhibits antiangiogenic and antitumor activity [1] . Sorafenib inhibits wild-type B-RAF, oncogenic B-RAF, C-RAF, c-KIT, fibroblast growth factor receptor 1 (FGFR1), platelet-derived growth factor receptor-β (PDGFR-β), and vascular endothelial growth factor receptor (VEGFR-1, VEGFR-2, VEGFR-3) [1] . Sorafenib is approved in the United States for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma (HCC) at the recommended dose of 400 mg orally twice daily [2] .
Sorafenib exhibits high inter-individual variability in pharmacokinetics with variable absorption (time to maximum concentration occurring between 2 and 12.5 h) and secondary peaks combined with a long elimination half-life (20-39 h) in cancer patients [3] [4] [5] [6] [7] [8] . Sorafenib undergoes oxidative metabolism by CYP3A4 and glucuronidation by UGT1A9 to 7 metabolites, in vitro and in vivo [6] . Sorafenib N-oxide, which is formed by CYP3A4-mediated metabolism, is the main circulating metabolite in plasma [6] . Despite wide variability in exposure, few investigations have reported a link between cumulative sorafenib dose or total sorafenib exposure and the pharmacodynamic effects or adverse effects [3] [4] [5] 8] . Pratz and colleagues demonstrated that a metabolite of sorafenib, sorafenib N-oxide, was a potent inhibitor of FLT3 in vitro, in a cell line-based plasma inhibitory assay, which was applicable ex vivo to leukemic blast samples as a pharmacodynamic measure of drug effects [7] . Pharmacokinetic variability may play a major role in impacting the treatment outcomes due to different local (tumor) and systemic exposure.
Unbound drug concentrations are believed to be more relevant to pharmacological and toxicological responses than total drug. Equilibrium dialysis has long been recognized as the gold standard in protein binding studies since determination of the binding constant (K) is obtained under physiological conditions at equilibrium [9, 10] . The use of a microequilibrium dialysis plate is a simple and reliable method that can simultaneously analyze up to 96 samples in smaller volumes than by traditional equilibrium dialysis methods.
Sorafenib is known to be extensively protein bound (>99.5%) with a low hepatic extraction ratio suggesting protein binding may play a major role in the sorafenib pharmacokinetic variability [2, 11] . Hypoalbuminemia and elevations in α 1 -acid glycoprotein (AAG) have been noted in cancer patients [12] . Additionally, hypoalbuminemia and to a lesser extent hyperbilirubinemia have been noted in patients receiving sorafenib [2] . Unconjugated bilirubin binds to albumin and increases in bilirubin may theoretically alter sorafenib binding. Therefore further characterization of the binding properties of sorafenib to healthy volunteer human plasma and individual proteins is warranted and was performed using a microequilibrium dialysis method. The method was then applied to evaluate binding in plasma from cancer patients receiving sorafenib at a dose of 400 mg and 600 mg twice daily.
Materials and methods

Chemicals and reagents
Sorafenib was provided by Bayer HealthCare (Wuppertal, Germany) or purchased from Toronto Research Chemicals (Ontario, Canada).
3 H-Sorafenib (specific activity 1.3-1.6 Ci/mmol; concentration 1.0 mCi/mL in ethanol; radiochemical purity of >97.7% by high-performance liquid chromatography) was purchased from Moravek Biochemicals Inc. (Brea, CA, USA). Human serum albumin (HSA, product # A9511, >97% pure) and human α 1 -acid glycoprotein (AAG, product # G9885, 99% pure) were obtained from Sigma-Aldrich Company (St. Louis, Missouri, USA). Bio-Safe II scintillation fluid was purchased from Research Products International (Mount Prospect, IL, USA). Phosphate buffer solution (PBS 1 X pH 7.4) was obtained from Quality Biological, Inc (Gaithersburg, Maryland, USA). Human plasma was purchased from Strough (formerly Plasmacare) (Cincinnati, OH, USA). All other chemicals used were of analytical grade.
Equilibrium dialysis method
Protein binding experiments were performed in plasma over a clinically relevant sorafenib concentration range of 7.26-14,520 ng/mL. Equilibrium dialysis was performed on a 96-well Equilibrium DIALYZER with a 5-kDa cut-off regenerated cellulose membrane (catalog # 74-2300; Harvard Apparatus, Holliston, MA, USA) on a rotator at 37°C in a humidified atmosphere of 5% CO 2 . Experiments were performed using a 200 μL aliquot of plasma containing unlabeled sorafenib spiked with tracer amount of 3 H-sorafenib against an equal volume of 1X PBS (pH 7.4). The optimal time to equilibrium was determined with human plasma samples containing 7.26, 1452 or 14,520 ng/mL sorafenib in quadruplicate at 2, 4, 6, 24 and 30 h after the start of the experiment. After dialysis, 100 μL aliquots of buffer (C u ) and plasma (C p ) were transferred to scintillation vials containing 5 mL of Bio-Safe II scintillation fluid. Radioactivity was measured on a Beckman LS-6000 TA scintillation counter (Beckman Instrument Inc., Columbia, MD, USA). Unbound sorafenib fraction (F u ) was calculated as F u ¼ C u =C p . The fraction was converted to percentage by multiplying F u by 100%.
Initial experiments were performed in human plasma to ascertain concentration-dependent binding at 6 concentration points (7.26, 14.52, 145.2, 1,452, 7,260, and 14,520 ng/mL) analyzed in quadruplicate. Validation of the equilibrium dialysis method was performed in human plasma at 3 sorafenib concentrations of 7.26, 1,452 and 14,520 ng/mL spiked with tracer amount of 3 H-sorafenib. The within-and between-run precisions were calculated after analysis of samples in quadruplicate on 5 days as described previously [13] . Drug recovery was calculated by comparing the initial radioactivity added to the plasma sample with the total radioactivity recovered in the plasma and buffer (PBS) fractions after dialysis. The impact of stability of sorafenib protein binding in human plasma was assessed during one freeze-thaw cycle.
In vitro binding experiments
The degree of sorafenib protein binding was assessed in isolated protein solutions containing either HSA or AAG as described above.
Estimation of the protein binding parameters
The total binding constants (nK) in plasma and isolated proteins (HSA and AAG) for sorafenib were calculated with the following assumptions: 1) plasma protein binding of sorafenib was linear at the clinically relevant concentration range (7.26-14,520 ng/mL) and 2) sorafenib bound to a single class of nonsaturable binding sites with no allosteric effects. Modified Scatchard plots were constructed using unbound sorafenib concentration (C u ) and the bound drug concentration (C b ) based on the following equations:
where P is the protein concentration and nK is the total binding constant (product of number of binding sites by affinity constant). nK × P is the slope of the regression line using Eq. (1), and C b , C u and P are expressed as molar concentrations (M). nK was also estimated by assessing the unbound drug fraction at varied protein concentration (0.25
SigmaPlot version 11.0 (Systat Software Inc., San Jose, CA, USA) was used for this analysis.
Determination of unbound sorafenib in patient plasma and pharmacokinetic analysis
To determine the fraction unbound of sorafenib in patients plasma, samples were obtained from 15 leukemia patients enrolled in a clinical trial at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD, USA). Sorafenib was administered as monotherapy at a dose range of 400 mg to 600 mg twice daily [7] . All patients provided written informed consent and the clinical protocol was approved by the Institutional Review Board (IRB). The fraction unbound (F u ) in patient plasma was determined using the method for the equilibrium dialysis as described above. The total drug concentration (C p ) was determined by a high-performance liquid chromatographic with tandem mass spectrometric method (LC/MS/MS) described previously [14, 15] . The unbound concentration (C u ) was calculated as F u × total drug concentration (C p ). Estimates of pharmacokinetic parameters for unbound sorafenib in plasma were calculated from individual concentration-time data sets by standard noncompartmental methods using WinNonlin Professional (version 5.3) as previously described [7] .
Statistical analysis
Statistical analysis was performed using JMP™ statistical discovery software version 7 (SAS Institute, Cary, NC, USA). All data were shown as mean ± standard deviation (SD) unless stated otherwise. One-way analysis of variance (ANOVA) with Tukey-Kramer post-hoc test was used for comparing the F u values of sorafenib among patients, gender, and over time and the varying concentrations in the in vitro analysis with HSA and AAG. After testing for normality in parameter value distribution, univariate linear-regression analysis was used to assess the relation between age, body-size indices, AAG, HSA, or total bilirubin and unbound sorafenib concentrations. All P-values were two-sided, not adjusted for multiple comparisons, and were considered significant at a P<0.05.
Results
Assay optimization and validation
The optimal equilibrium time was established at 24 h (Fig. 1) . Sorafenib was extensively bound to human plasma proteins with a F u of 0.31±0.02% in a concentration independent (non-saturable) manner at the clinically relevant concentrations (i.e., 7.26-14,520 ng/mL). The assay was accurate and reproducible as the within-and betweenrun precisions were <5.1% from assessment of samples in quadruplicate on 3 separate days. Plasma containing 7.26 and 14,520 ng/mL sorafenib was analyzed for F u in quadruplicate before and after a single freeze-thaw cycle. The mean F u values were 0.32% and 0.29% before and after the freeze-thaw cycle, respectively, suggesting no significant influence of thawing on protein binding (P>0.05).
The overall recovery for [ 3 H]-sorafenib was found to be 97.7%.
Binding to plasma proteins
In isolated protein solution 99.8±0.02% and 79.3±4.5% of sorafenib was bound to HSA (40 mg/mL) and AAG (1 mg/mL), respectively. The binding of sorafenib to both proteins was concentration independent at 7.26 to 14,520 ng/mL. Using method 1 (Eq. 1) the total binding constant (nK) for sorafenib was 9.05×10 5 M −1 (R 2 =1.00, R = 1.00, P < 0.0001) and 1.36 × 10 −5 M −1 (R 2 = 0.99, R = 0.99, P < 0.0001) to HSA and AAG respectively. Sorafenib binding at a fixed concentration of 72.6 μg/mL was concentration-dependent; with F u % decreasing as HSA increased from 0.5 to 4.0 g/dL and as AAG increased from 0.01 to 0.25 g/dL. Using a nonlinear regression analysis according to Eq. (2) , respectively.
Unbound fraction of sorafenib in patient plasma
Unbound fraction of sorafenib was calculated in 15 patients enrolled in a clinical trial receiving sorafenib at 400 mg or 600 mg twice daily. Demographic data for these patients are presented in Table 1 . In patients receiving 400 mg the F u % was calculate as 0.29±0.03%. For patients receiving 600 mg twice daily the F u % was calculated as 0.31±0.03%. No significant variation in sorafenib F u % was observed during the 28 days of treatment among the 15 patients included in the trial (9.3% CV, P>0.05) (Fig. 2a) suggesting a day 1 pretreatment specimen could be utilized to assess an individual patient's sorafenib F u %. The sorafenib F u % was consistent over the range of total sorafenib concentrations (slope=4.6×10 ; 95% CI=−1.3×10 −6 to 2.3×10 6 ; Fig. 2b ). The variability in the pharmacokinetic parameters of unbound and total sorafenib was nearly identical suggesting protein binding may not account for inter-subject variation (Table 2) . Age, body-size indices, gender, and pre-treatment 
Discussion
Sorafenib is a multikinase inhibitor that impacts many cellular processes that has highly variable pharmacokinetic and pharmacodynamic effects. A further understanding of the contribution of the clinical pharmacology, including protein biding as well as sorafenib metabolites, to its clinical activity is necessary. A semi-high throughput equilibrium dialysis method has been optimized and validated to determine the fraction unbound of sorafenib in plasma. Sorafenib exhibited extensive binding in human plasma (99.7%), specifically being mainly bound to plasma proteins HSA (99.8%) and to a lesser extent AAG (79.3%). Utilizing the total binding constants, sorafenib has an 8.8-fold higher affinity for albumin.
A previously published manuscript has explored the protein binding of sorafenib to plasma proteins at varying drug but constant protein concentration using fluorescence AUC C u /C p (%) n/a n/a 0.29±0.02 (11) 0.30±0.004 (3) Data were obtained from patients receiving sorafenib orally, and are presented in the table as mean values ± SD (n). T max is presented as median (range; n). If n<3, the actual values are reported a Accumulation factor was calculated from the ratio of C min, ss /C min, first dose AUC 0-8h area under the plasma concentration-time curve to 8 h; C max peak plasma concentration; C ss, min minimal plasma concentration at steady state (average of day 8 and 15 C min) ; C u unbound sorafenib concentration; C p total sorafenib concentration; T max time to peak concentration quenching [16] . The binding constant for albumin was similar (3.00×10 6 M −1 ) but a higher affinity was noted for AAG (1.54×10 6 M −1 ) and therefore results in only a 2-fold higher affinity for albumin [16] . Since this method is not applicable to patient samples, Tod and colleagues performed correlations with total sorafenib concentrations and have concluded that albuminemia may influence the pharmacology of sorafenib. Correlations were not noted in the present study using actual unbound sorafenib concentrations highlighting the importance of studying alterations in protein binding in patient samples using the more thermodynamically sound and clinically applicable method. Consistent with the in vitro data, sorafenib was bound in cancer patient's plasma at 99.7% over a duration of 28 days. Although sorafenib has a higher affinity for albumin, neither pre-treatment albumin nor AAG were predictive of unbound sorafenib in patients. Despite the unclear correlation, it is still possible that the 7-fold variation in AAG concentrations or variable albumin concentrations secondary to malnutrition in cancer patients may have an impact on the unbound sorafenib concentrations [12, 17] . Pharmacokinetic analysis of unbound sorafenib concentrations exhibited similar inter-subject variation suggesting that protein binding may not be an important factor in sorafenib pharmacokinetic monitoring in cancer patients. Since sorafenib is FDA approved as a single agent and not in combination, displacement studies with adjuvant drugs were not performed. Sorafenib F u in patients was consistent over time and a clinically achievable concentration range despite receiving a variety of concomitant medications. These results suggest that sorafenib is not displaced from plasma proteins. However, future studies in a larger patient population with a variety of concomitant medications would be necessary to determine whether clinically significant alteration in sorafenib F u can occur via displacement from plasma proteins. In conclusion, sorafenib is highly bound in human plasma mainly to albumin and AAG suggesting that limited free drug may be partly responsible for its variable clinical activity.
